Tandem Diabetes receives FDA clearance for t:slim X2 pump and Control-IQ for children 2+

TANDEM DIABETES CARE INC

FDA cleared 510(k) applications for t:slim X2 insulin pump and Control-IQ technology enhancements on Nov 3, 2023.
Expanded pediatric indication now includes individuals two years of age and older.
This clearance broadens the eligible patient population for Tandem's automated insulin delivery system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.